Cat. No：GM-88254MAB
Product：Anti-Mouse_PD1×VEGF hIgG1 Bispecific Antibody
Cat. No：GM-88254MAB
Product：Anti-Mouse_PD1×VEGF hIgG1 Bispecific Antibody
GM-88254MAB-1mg / 1 mg
GM-88254MAB-5mg / 5 mg
GM-88254MAB-25mg / 5 mg * 5 vials
GM-88254MAB-50mg / 50 mg
GM-88254MAB-100mg / 50 mg * 2 vials
Expression System | CHO |
Aggregation | < 5% as determined by SEC-HPLC |
Purity | > 95% as determined by SDS-PAGE |
Endotoxin | < 1 EU/mg, determined by LAL gel clotting assay |
Sterility | 0.2 μm Filtered |
Target | VEGF&PD1 |
Alternative Names | PD1: CD279 VEGF: VPF; MVCD1; L-VEGF |
Source/Isotype | Monoclonal human IgG1 D265A, Kappa |
Application | Flow cytometry; Block assay |
Description | PD-1/VEGF Bispesific Antibody is a novel cancer immunotherapy drug that can target both PD-1 and VEGF. It blocks the interaction between PD-1 and PD-L1/PD-L2. The bispecific antibody can specifically bind to VEGFA and PD-1, selectively relieve the immune suppression caused by VEGFA and PD-1 in the body, and inhibit tumor-induced angiogenesis. |
Formulation | 20 mM Histidine, 150 mM NaCl, pH6.0 |
Cat. No：GM-88254MAB
Product：Anti-Mouse_PD1×VEGF hIgG1 Bispecific Antibody
Cat. No：GM-88254MAB
Product：Anti-Mouse_PD1×VEGF hIgG1 Bispecific Antibody
GM-88254MAB-1mg / 1 mg
GM-88254MAB-5mg / 5 mg
GM-88254MAB-25mg / 5 mg * 5 vials
GM-88254MAB-50mg / 50 mg
GM-88254MAB-100mg / 50 mg * 2 vials
GM-88254MAB-1mg / 1 mg
GM-88254MAB-5mg / 5 mg
GM-88254MAB-25mg / 5 mg * 5 vials
GM-88254MAB-50mg / 50 mg
GM-88254MAB-100mg / 50 mg * 2 vials
Expression System | CHO |
Aggregation | < 5% as determined by SEC-HPLC |
Purity | > 95% as determined by SDS-PAGE |
Endotoxin | < 1 EU/mg, determined by LAL gel clotting assay |
Sterility | 0.2 μm Filtered |
Target | VEGF&PD1 |
Alternative Names | PD1: CD279 VEGF: VPF; MVCD1; L-VEGF |
Source/Isotype | Monoclonal human IgG1 D265A, Kappa |
Application | Flow cytometry; Block assay |
Description | PD-1/VEGF Bispesific Antibody is a novel cancer immunotherapy drug that can target both PD-1 and VEGF. It blocks the interaction between PD-1 and PD-L1/PD-L2. The bispecific antibody can specifically bind to VEGFA and PD-1, selectively relieve the immune suppression caused by VEGFA and PD-1 in the body, and inhibit tumor-induced angiogenesis. |
Formulation | 20 mM Histidine, 150 mM NaCl, pH6.0 |
Expression System | CHO |
Aggregation | < 5% as determined by SEC-HPLC |
Purity | > 95% as determined by SDS-PAGE |
Endotoxin | < 1 EU/mg, determined by LAL gel clotting assay |
Sterility | 0.2 μm Filtered |
Target | VEGF&PD1 |
Alternative Names | PD1: CD279 VEGF: VPF; MVCD1; L-VEGF |
Source/Isotype | Monoclonal human IgG1 D265A, Kappa |
Application | Flow cytometry; Block assay |
Description | PD-1/VEGF Bispesific Antibody is a novel cancer immunotherapy drug that can target both PD-1 and VEGF. It blocks the interaction between PD-1 and PD-L1/PD-L2. The bispecific antibody can specifically bind to VEGFA and PD-1, selectively relieve the immune suppression caused by VEGFA and PD-1 in the body, and inhibit tumor-induced angiogenesis. |
Formulation | 20 mM Histidine, 150 mM NaCl, pH6.0 |
